Post-neoadjuvant strategies in breast cancer: From risk assessment to treatment escalation

The post-neoadjuvant setting in early breast cancer represents an attractive scenario for adjuvant clinical trials, offering the opportunity to test new drugs or combinations in high-risk patients who did not achieve pathologic complete response after primary treatment. No standard therapies are routinely proposed to patients with residual disease after neoadjuvant chemotherapy and few trials have explored this setting. To date, only one randomized phase III study showed the benefit of additional capecitabine after neoadjuvant chemotherapy, and international guidelines recommend at least to consider its use, particularly for triple negative breast cancer. Therefore, the management of these patients is still a clinical challenge, with limited data supporting the use of an additional adjuvant non-cross-resistant chemotherapy. Escalation strategies are currently under evaluation, with new agents proposed as supplementary post-neoadjuvant treatment (e.g. platinum salts, capecitabine, poly ADP-ribose polymerase inhibitors, immune checkpoint inhibitors, cyclin-dependent kinase 4/6 inhibitors). Based on these premises, selection criteria are critical to identify patients who may benefit from post-neoadjuvant therapies, through the validation of prognostic and predictive biomarkers for a reliable risk assessment and estimation of benefit.The present review summarizes the efforts in introducing new therapeutic options for patients with breast cancer and residual disease after neoadjuvant treatment, with a particular focus on the ongoing clinical trials and useful biomarkers for risk stratification.     

肝癌介入术治疗患者术中应用心理护理的效果

目的研究在肝癌介入术治疗患者中应用心理护理干预的临床价值。方法本文数据计算目标是2018年1月-2019年6月的60例肝癌介入术治疗患者,以随机数字表法的形式进行分组研究,常规组(n=30)开展一般护理干预,心理组(n=30)开展心理护理干预,比较心理组与常规组肝癌介入术治疗患者临床护理情况。结果心理组肝癌介入术治疗患者治疗后临床护理满意度、焦虑评分、抑郁评分与常规组比较,两组治疗后肝癌介入术治疗患者焦虑评分、抑郁评分与治疗前比较,P<0.05,差异有统计学意义。结论将心理护理干预应用在肝癌介入术治疗患者中可提升护理满意度。     

Addressing Substance Use in Adolescents: Screening,Brief Intervention,and Referral to Treatment

Adolescent substance use is a national public health crisis. The most commonly used substances among adolescents are nicotine, alcohol, and marijuana. Use of these substances during adolescence has serious adverse effects on brain development, with impairments that can endure into adulthood. Advanced practice nurses in primary care can address substance use in the adolescent population with the use of evidence-based interventions, such as Screening, Brief Intervention, and Referral to Treatment (SBIRT). This article describes trends in adolescent substance use and use of the SBIRT intervention for low, medium, and high-risk use in this population.     

实体化创伤中心建设提升严重创伤救治能力

为明确实体化创伤中心建设对提升严重创伤救治能力的作用,笔者以兴义市创伤中心实体化建设后所取得的初步成效,从院内多学科团队建设及核心能力维护、创伤救治流程优化、创伤时间节点质量控制与持续改进等方面进行介绍,为实体化创伤中心建设提供借鉴和参考。     

肝内胆管癌新辅助治疗共识与争议

肝内胆管癌（ICC）恶性程度高，症状隐匿，早期症状不明显，由于缺乏有效的筛查，确诊时多处于进展期，大多失去手术切除机会。目前，根治性手术仍是惟一可以使病人获得长期生存的治疗方式，但存在切除率低、术后易复发等难题。新辅助治疗能缩小原有病灶及转移的淋巴结，提高R0切除率，对于无法切除的局部晚期ICC，新辅助治疗可使局部进展的ICC降期为可切除，也可改善肝移植病人的预后。但目前对ICC行新辅助治疗的潜在效用仍存在争议。     

延续护理干预对慢性乙型肝炎患者抗病毒治疗依从性的影响观察

目的:分析延续护理干预对慢性乙型肝炎患者抗病毒治疗依从性的影响。方法:研究选取2017年1月~2017年12月某院肝二病区收治的112例乙型肝炎患者和2018年1月~2018年12月收治的98例乙型肝炎病毒患者作为研究对象,所有患者均进行抗病毒治疗,回顾性分析患者的病历资料。将2017年收治的112例患者作为常规组实施常规护理,将2018年收治的98例患者的作为研究组实施延续性护理,比较两组的护理效果。结果:研究组的治疗依从率为93.88%(92例),远高于常规组的77.68%(87例),两组数据比较存在统计学意义(P<0.05)。结论:延续性护理措施可以有效提高慢性乙型肝炎抗病毒治疗的依从性,可以在临床中推广使用。     

我国类鼻疽病的流行病学特征及诊疗的研究进展

类鼻疽病是由类鼻疽伯克霍尔德菌(Burkholderia pseudomallei)感染引起的一类人畜共患病,主要流行于全球热带及亚热带地区。在我国主要流行于南部地区,疫源地为海南、广东、广西、台湾等。伴随着旅游业和贸易业的发展,我国其他非疫区出现了输入性病例。类鼻疽病的感染途径主要为经伤口、粘膜、呼吸道、消化道等,其病变可涉及机体所有器官,易造成较高的误诊率和病死率。然而我国目前类鼻疽病的流行病筛查技术存在一定的局限性,在防控方面未实行有效的疾病监测和疾病报告制度,对基层医师和民众疾病知识普及的力度不够。因此,本文旨在提高我国医务工作者对类鼻疽病的重视程度,从类鼻疽病的病原学特征、流行病学特征、临床特征、诊断与治疗、防控措施这五个方面进行详细综述。     

Osteoarthritis today: Lost in translation?

Osteoarthritis (OA) is a highly prevalent joint disease that is associated with pain, loss of function, and high direct and indirect economic costs. The current therapeutic options are inadequate, providing only a moderate symptom relief without the possibility of disease modification. While treatment options and personalized medicines are increasing for many complex diseases, OA drug development has been impeded by the advanced state of disease at the time of diagnosis and intervention, heterogeneity in both symptoms and rates of progression, and a lack of validated biomarkers and relevant outcome measures. This review article summarizes the OA landscape, including therapies in development as potential OA treatments, potential biomarkers undergoing evaluation by the US Food and Drug Administration, and a summary of current OA treatment guidelines, with a particular focus on the knee OA.     

Instrument-based Tests for Measuring Anterior Chamber Cells in Uveitis: A Systematic Review

ABSTRACT

Purpose

New instrument-based techniques for anterior chamber (AC) cell counting can offer automation and objectivity above clinician assessment. This review aims to identify such instruments and its correlation with clinician estimates.